WOODBRIDGE, ON, May 13, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced that it
has engaged Brandkarma LLC., an award winning, US-based, healthcare
marketing and brand specialist with global expertise to support the
Company's commercialization strategy for VASCAZEN®.
"VASCAZEN® represents a much-needed solution for Omega-3 deficiency. Healthcare
providers and the general public at large need to know the serious
health risks associated with this deficiency. We are proud to be a part
of the team tasked with bringing this brand to the market," stated Ken
Ribotsky, President and CEO of Brandkarma. Brandkarma's client list
includes some of the largest healthcare companies in the world and has
established itself as a leader in the medical food arena.
"We are very excited to have Brandkarma as our marketing partner,"
stated Ms. Rachelle MacSweeney, President and COO. "With the closing
of the financing on March 4, Pivotal finally has the resources to
execute its marketing plan and implement its strategy to effectively
penetrate US market opportunities for VASCAZEN®. We would also like to thank our investors and shareholders for their
continued support and patience as we embark on this next stage of
commercialization and make VASCAZEN® a success," added Ms. Rachelle MacSweeney, President and COO.
VASCAZEN® is currently available in the U.S. as a prescription only medical food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and an increase of
HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Brandkarma LLC.
Brandkarma LLC. is a strategic marketing consulting and healthcare
communications company for specialty pharmaceutical, biotech, medical
device, diagnostic and health service companies. Clients collaborate
with Brandkarma's highly specialized and experienced strategists to
tackle everything from brand (re)positioning and market landscaping to
strategic and creative brand development, advertising and promotion,
sales force programs, corporate communications, corporate identity,
digital and social media, and public relations. Learn more about Brandkarma at the award-winning website brandkarma.org.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada
The information contained in this document is as of May 13, 2014. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast", "intend",
"plan", "believe", "project", "potential", and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company's
products will not gain widespread market acceptance; risks relating to
the Company's ability to maintain its CSE listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
Image with caption: "VASCAZEN® a prescription only medical food for the dietary management of an Omega 3 deficiency in Cardiovascular patients. (CNW Group/Pivotal Therapeutics Inc.)". Image available at: http://photos.newswire.ca/images/download/20140513_C8112_PHOTO_EN_40243.jpg